Galapagos NV. announced its plans to split into two listed entities by mid-2025 by spinning off its activities focused on ...

Global leaders must urgently prioritise and work to provide access to new long-acting HIV prevention -- and potentially ...

Even before the FDA's recent approval of Dato-DXd in breast cancer, analysts predicted sales of the antibody-drug conjugate ...

The global precision diagnostics and medicine market, valued at US$132.46 billion in 2023, is forecasted to grow at a robust CAGR of 11.1%, reaching US$145.53 billion in 2024 and an impressive US$246.

It’s all the more tragic because HIV drugs can keep people from catching the virus, and prevent those living with the virus from passing it on. If everyone who needed these drugs could access them, ...

The clearance of Datroway comes months after the companies narrowed approval plans in lung cancer and opens up a market ...

So far, the FDA has approved the drug only for people who already have HIV that’s resistant to other treatments. But its ...

The commitment of organizations like the Cystic Fibrosis Foundation to global research funding and access initiatives has further propelled market growth. Additionally, major pharmaceutical companies, ...

Extended-course nirmatrelvir/ritonavir yields a meaningful reduction in symptoms for some patients with long COVID, but not all benefits persist.

Here are 10 healthcare industry lawsuits, settlements and legal developments that Becker's has reported since Jan. 14: ...

Gilead Sciences Inc. is moving further into inflammatory diseases in a potential $1.7 billion deal with Leo Pharma A/S around a preclinical oral signal transduction and activator of transcription 6 ...